NCT04725812View on ClinicalTrials.gov

Complement Regulation to Undo Systemic Harm in Preeclampsia

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 13, 2021

Primary Completion Date

December 7, 2021

Study Completion Date

December 7, 2021

Conditions
PreeclampsiaSevere PreeclampsiaEculizumabHELLPHELLP SyndromeHELLP Syndrome Second TrimesterPregnancy RelatedAHUSPNHComplement Regulatory Factor DefectComplement AbnormalityHELLP Syndrome Third Trimester
Interventions
DRUG

Eculizumab

Eculizumab Intravenous Solution

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

Sponsors
All Listed Sponsors
collaborator

Alexion Pharmaceuticals, Inc.

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER